An effort by President Trump's administration to curb advertising for pharmaceutical drugs on television is posing creating a potential marketing hurdle for some of the country's largest drugmakers while threatening a key revenue stream for media companies.

Advertising and pharmaceutical industry experts say an executive order Trump signed this week could pose an existential threat to the business model of both drugmakers and the media companies which raked in an estimated $5 billion in advertising revenue from pharmaceutical companies in 2024.

The order instructs the Department of Health and Human Services to ensure “transparency and accuracy” in direct-to-consumer advertising, including requiring greater disclosures of side effects in television and other ads.

The order stops short of directing an outright ban on drug advertisements, though HHS Secretary Robert F. Kennedy Jr. has called for a wholesale end to direct-to-consumer advertising for prescription drugs.

“This is a shot across the bow from the administration telling these companies we’re watching you, get your act together or we’re going to come after you,” said Robin Feldman, an expert in health law and a professor at the University of California. “The tone of the message matters as much as the language here.”

The administration has sent firm cease and desist letters to........

© The Hill